DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Mizuho Initiates Coverage On Biohaven Pharmaceutical with Buy Rating, Announces $62 Price Target

Mizuho analyst Vamil Divan initiates coverage on Biohaven Pharmaceutical (NYSE:BHVN) with a Buy rating and a $62 price target.

Benzinga · 02/06/2020 10:07

Mizuho analyst Vamil Divan initiates coverage on Biohaven Pharmaceutical (NYSE:BHVN) with a Buy rating and a $62 price target.